Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Adipose tissue-derived stromal cells (ADSCs) are a population of multipotent mesenchymal stem cells (MSCs) isolated from adipose tissue. These cells possess the capability to differentiate into various cell types, including hepatocyte-like cells, and are characterized by their ability to secrete a wide array of paracrine factors that promote tissue repair, immunomodulation, and angiogenesis. In the context of liver cirrhosis, ADSCs are being investigated for their potential to facilitate liver regeneration by reducing inflammation and fibrosis while stimulating the proliferation of endogenous hepatocytes. Kanazawa University has conducted Phase 1 clinical trials evaluating the safety and efficacy of autologous ADSCs delivered via intra-hepatic artery infusion for patients with liver cirrhosis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on adipose tissue-derived stromal cells.